Atrovent and Thrombotic microangiopathy - a phase IV clinical study of FDA data

Summary:

Thrombotic microangiopathy is reported as a side effect among people who take Atrovent (ipratropium bromide), especially for people who are female, 0-1 old, also take Pulmozyme, and have Spinal muscular atrophy.

The phase IV clinical study analyzes which people have Thrombotic microangiopathy when taking Atrovent. It is created by eHealthMe based on reports of 33,026 people who have side effects when taking Atrovent from the FDA, and is updated regularly.

What is Atrovent?

Atrovent has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 33,210 Atrovent users. Check the latest studies of Atrovent.

What is Thrombotic microangiopathy?

Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury) is found to be associated with 475 drugs and 672 conditions by eHealthMe. Check the latest studies of Thrombotic microangiopathy.

On Jul, 04, 2026

33,026 people reported to have side effects when taking Atrovent.
Among them, 28 people (0.08%) have Thrombotic microangiopathy.

Could Atrovent cause Thrombotic microangiopathy?

Among these 28 people:

What is the gender of people who have Thrombotic microangiopathy when taking Atrovent? *

female: 82.14 %
male: 17.86 %

What is the age of people who have Thrombotic microangiopathy when taking Atrovent? *

What are other drugs people take besides Atrovent? *

What are other side effects people have besides Thrombotic microangiopathy? *

Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 21 people, 75.00%
High Blood Pressure: 19 people, 67.86%
Blood Creatinine Increased: 19 people, 67.86%
Hypotension (abnormally low blood pressure): 19 people, 67.86%
Microangiopathic Haemolytic Anaemia (anaemia due to inability of bone marrow to compensate the premature destruction of red blood cells): 19 people, 67.86%
Thrombocytopenia (decrease of platelets in blood): 19 people, 67.86%
Pasteurella Infection: 18 people, 64.29%
Agitation (state of anxiety or nervous excitement): 18 people, 64.29%
Haematuria (presence of blood in urine): 18 people, 64.29%
Haemolytic Anaemia (anaemia due to haemolysis): 18 people, 64.29%

What are the existing conditions these people have? *

Spinal Muscular Atrophy (wasting of spinal muscles): 18 people, 64.29%
Respiratory Tract Infection: 12 people, 42.86%
Lung Disorder (lung disease): 6 people, 21.43%
Indigestion: 2 people, 7.14%
Cytomegalovirus Infection: 2 people, 7.14%
Adenocarcinoma Pancreas (cancer of pancreas): 2 people, 7.14%
High Blood Pressure: 1 person, 3.57%
Herpes Zoster: 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Atrovent and have Thrombotic microangiopathy?

- Check whether Thrombotic microangiopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atrovent:

Atrovent (33,210 reports)

Browse all side effects of Atrovent:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thrombotic microangiopathy:

Thrombotic microangiopathy (475 drugs)

Browse all the conditions that are associated with Thrombotic microangiopathy:

Thrombotic microangiopathy (672 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ipratropium bromide (the active ingredients of Atrovent) and Atrovent (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.